Articles tagged with Breast Cancer
Researchers are identifying genetic biomarkers in patient blood samples to predict aggressive breast cancer progression. Large oncosomes, tumor-derived vesicles, may serve as valuable insights into disease progression.
A California-based group has developed a website to address the implications of breast density notification laws, which require patients with dense breasts to receive written notification. The group recommends an individualized risk-based approach to guiding decision-making on supplementary screening.
A new analysis reveals that regular mammograms before age 50 significantly reduce breast cancer deaths in younger women. The study analyzed data from invasive breast cancers diagnosed between 1990 and 1999, finding that only 13% of cases occurred in women aged 70 or older.
A new analysis confirms the importance of regular mammography screening in reducing breast cancer deaths, especially among younger women. The study found that 71% of confirmed breast cancer deaths occurred in the 20% of patients who did not receive annual mammograms.
Researchers identified a gene mutation that predisposes children to the most common form of childhood leukemia. The PAX5 mutation was found in multiple generations of two families, leading to a marked reduction of normal PAX5 activity in leukemia cells.
A new study from Memorial Sloan Kettering Cancer Center found that MRI use in women with early breast cancer did not reduce local recurrence or contralateral breast cancer rates. The study, which looked at over 2,300 patients, suggests that the benefits of MRI may be limited to other patient groups.
Studies find radiation therapy for DCIS does not increase cardiovascular disease risk, while MRI scans may be unnecessary. Additionally, most women have inaccurate perceptions of their personal breast cancer risk, sparking the need for better communication between patients and doctors.
A new study found that hormone replacement therapy (HRT) use is associated with an increased risk of breast cancer among postmenopausal women, but the relationship varies depending on factors such as race/ethnicity, body mass index (BMI), and breast density. The study suggests that HRT may be used for some women without increasing thei...
Researchers found that ERBB3 expression was enhanced in luminal breast cancers compared to other subtypes. The addition of an ERBB3 antibody promoted cancer cell death and decreased tumor growth in vitro.
Researchers have identified a potential new target for breast cancer treatment: ERBB3, an oncogene that promotes tumor growth. The study also found peritoneal dialysis to be effective in reducing brain damage after stroke by lowering glutamate levels.
Researchers identified a protein that correlates with breast cancer aggressiveness and may predict prognosis; small molecule inhibitors could be developed as therapeutic drugs for breast cancer treatment.
Researchers from Notre Dame and Moi University are examining the unique manifestation of breast cancer in Kenya. The collaboration aims to identify novel insights into the mechanisms of breast cancer progression, which could ultimately help women worldwide.
Research from Washington University School of Medicine links increased breast cancer risk to drinking between early adolescence and first full-term pregnancy. Drinking daily can increase risk by 13% if averaged during this period, according to the study.
A recent study published in Critical Reviews in Oncology/Hematology found that calcium and vitamin D supplements do not prevent bone mineral density loss in women undergoing breast cancer treatment. Women with breast cancer experience a higher rate of bone loss than healthy counterparts, increasing their risk of fractures.
Researchers at Mayo Clinic have discovered that decitabine can halt the ability of cancer cells to separate from a tumor and spread to distant organs. The study found that treating genes silenced in aggressive triple negative breast cancer with decitabine may promote re-expression of PRKD1.
A multicenter trial found that BI-RADS 3 breast lesions have a malignancy rate of 0.8%, with most cancers detected at 12-month follow-up imaging. The study suggests that extending the follow-up interval from six to 12 months for these lesions may reduce unnecessary biopsies and exams.
A study by an international consortium of researchers found that reducing the expression of NEET proteins significantly reduced cancer cell proliferation and tumor size. The overabundance of these proteins is linked to the progression of the disease, making them a prime target for anticancer drugs.
A new analysis found that breastfeeding for over 6 months may safeguard nonsmoking mothers against breast cancer, with a 10-year delay in diagnosis compared to shorter breastfeeding periods. In contrast, smoking mothers did not benefit from longer breastfeeding
A new study from the University of Michigan Comprehensive Cancer Center found that nearly 20% of women did not believe their breast cancer risk, citing concerns about family history and personal health habits. The study highlights the need for improved communication and understanding of risk information to make informed medical decisions.
A study by Yale School of Medicine researchers found a significant increase in preoperative breast MRI use among older women with breast cancer, leading to more aggressive surgical treatment. Women who received an MRI were more likely to undergo bilateral mastectomy and contralateral prophylactic mastectomy.
A UCLA study found that women diagnosed with breast cancer who created personal websites experienced reduced depressive symptoms, improved mood, and increased appreciation for life. The project, Project Connect Online, provided a platform for breast cancer patients to share their experiences and connect with friends and family online.
A study led by Boston Children's Hospital researchers found that triple-negative breast cancers rely on active proteasomes to survive. Inhibiting these proteins with existing medications like bortezomib may offer new treatment options for this aggressive type of cancer.
Researchers found that regulatory elements (DEREs) control multiple target genes in response to estrogen stimulation, contributing to tumor development. Decreasing DERE copies may have therapeutic potential for treating women with estrogen receptor-positive breast cancers.
Researchers discovered that early pregnancy reduces mammary gland progenitor cells, which can divide into milk-producing cells, reducing the risk of breast cancer. The study aims to develop a protective treatment mimicking the effects of early childbearing.
Researchers discovered the OGF-OGFr axis can inhibit proliferation in human triple-negative breast cancer cells, reducing growth within 24 hours. The therapy also confers protection against paclitaxel treatment, a standard breast cancer therapy, and has minimal side effects.
Researchers have developed a strain of engineered rice that produces a rotavirus-specific antibody, protecting both normal and immune-deficient mice from the disease. This study provides a low-cost strategy for preventing rotavirus infection.
Researchers at Duke University found that tumor microenvironment alterations promote cancer progression by altering signaling in tumor-associated immune cells. The study supports the use of TGF-β inhibitors to enhance therapy efficacy.
Researchers found that AXL receptor pairs with EGFR to make tumors resistant to ErbB inhibitors. Combining drugs targeting AXL and EGFR receptors could offer a better way to fight tumors, according to the study.
A global study found that tamoxifen halves the breast cancer risk for women with BRCA1 or BRCA2 mutations. The medication has been used to treat breast cancer for decades and also prevents new cancers in many women.
A study of 602 new mothers found that extroverted and emotionally stable individuals are more likely to breastfeed and continue breastfeeding. Mothers who were introverted or anxious faced challenges with breastfeeding, including feelings of self-consciousness and difficulty accessing support services.
A QUT study found that extensive breast cancer surgery is linked to an increased risk of developing arm lymphoedema. The study revealed one in five women may be diagnosed with the condition, which can cause anxiety, depression, and emotional distress.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have successfully combined cellular therapy and gene therapy in a mouse-model system to develop a viable treatment strategy for breast cancer that has spread to the brain. The approach shows significant promise in reducing metastatic brain tumor size, providing new hope for pati...
A population-based study found that current use of calcium-channel blockers for 10 or more years was associated with a higher risk of ductal and lobular breast cancer. The relationship did not vary based on the type of calcium-channel blockers used, with other antihypertensive medications showing no increased risk.
A new study by Fred Hutchinson Cancer Research Center scientists found that long-term use of calcium-channel blockers increases the risk of invasive ductal and lobular cancers. The study suggests alternative options for managing hypertension may be beneficial for reducing breast cancer risk.
HudsonAlpha and UAB researchers aim to identify optimal treatments for ER+ breast cancer using tumor genomics. By analyzing genetic data from patients who responded or didn't respond to treatment, they hope to develop targeted therapies.
The lack of investment in tumor biomarker research, inconsistent regulatory rules, and inadequate payment have created a vicious cycle preventing the development and testing of reliable biomarker tests. Experts recommend reforms to break this cycle and increase the value of tumor biomarker tests.
A new study published in Radiology found that digital tomosynthesis reduces the recall rate in breast cancer screening, particularly in younger women and those with dense breast tissue. The addition of tomosynthesis resulted in a 30 percent reduction in overall recall rate, compared to conventional mammography alone.
Researchers developed statistical models that predict individual women's risk of each cancer based on commonly known risk factors. The models were able to accurately calculate risk ranges from 0.5% to 29.5% over the next 20 years, providing a valuable tool for clinical decision-making.
Researchers at the University of Kentucky Markey Cancer Center have made significant discoveries about the Par-4 gene and its role in cancer recurrence. The study found that low levels of Par-4 protein may predict breast cancer relapse, while high levels can eliminate cancer cells through apoptosis.
Researchers at Lund University found that lymph nodes provide a more accurate picture of breast cancer prognosis than breast tissue alone. Analyzing the proliferation, hormone receptor status, and HER2 status of lymph nodes showed significantly improved results in predicting metastases and disease recurrence.
Singapore scientists have identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. UBASH3B is a protein tyrosine phosphatase that promotes tumor growth and metastasis in triple-negative breast cancer patients.
Undergraduate students at University of Houston are conducting research on Alzheimer's diagnostics, breast cancer treatment, and fruit fly courtship patterns. Their projects aim to develop new diagnostic methods and treatments, while exploring adaptations to environmental changes.
A large study of 23,000 people in Italy and Switzerland found a strong link between family history of cancer and increased risk of developing different types of cancer. The study revealed associations between specific cancers, such as oral and pharyngeal cancer, ovarian cancer, and prostate cancer, with a range of risk increases
Scientists at Ohio State University have identified two regions on the HER1/EGFR receptor as potential targets for peptide-based cancer vaccines and therapeutic agents. These peptides show promise in inhibiting tumor growth in breast and lung cancer models.
A study of 5-year survival rates among black and white women with breast cancer found that black women continued to have a lower rate of survival. The difference was largely attributed to factors such as poorer health at diagnosis and more advanced disease, rather than treatment differences.
Researchers have discovered a novel approach to combat hormone-resistant breast cancer, exploiting the epigenetic 'silencing' of the BCL-2 gene. This process may be detectable in blood samples, offering a diagnostic marker for resistant tumors.
Researchers have found that elevated levels of a receptor protein called Ret are associated with lower survival rates in breast cancer patients. Inhibiting this protein may be a promising approach to treating the disease.
Women who survive cancer have more frequent, severe, and troubling hot flashes than other women with menopausal symptoms. However, the study also found that the cancer survivors reported better psychological and social well-being, similar levels of sexual activity and function compared to women without cancer.
A pilot study by TGen and Scottsdale Healthcare shows that personalized cancer treatment based on molecular profiling improves clinical benefits, with 52% of advanced breast cancer patients experiencing disease control. The study demonstrates feasibility of personalized cancer treatment and sets the stage for a larger study.
A new study published in the Journal of the National Cancer Institute found that epoetin alfa can help alleviate anemia in high-risk breast cancer patients while maintaining overall and relapse-free survival rates. However, the treatment may increase the risk of thrombotic events.
A study found that a walnut-enriched diet reduced prostate cancer formation by 18% and slowed tumor growth. The results suggest that using walnuts on a regular basis may be beneficial in deferring or preventing certain types of cancer, including breast cancer.
Cardiovascular screening is crucial for cancer patients who received chest radiation, especially those at high risk of developing radiation-induced heart disease (RIHD). The European Society of Cardiology recommends regular screenings to detect cardiac abnormalities and reduce the risk of death from coronary artery disease.
Researchers at the University of Minnesota have discovered that APOBEC3B, a human antiviral enzyme, causes DNA mutations that lead to several types of cancer. The enzyme was found to be significantly elevated in six types of cancer and produced a unique mutational signature that matches the actual mutation pattern in these cancers.
A recent study found that the protein Tissue Factor promotes the growth of both metastatic pancreatic cancer and primary breast cancer. Researchers identified a novel monoclonal antibody targeting this protein, which showed promise in stopping tumor growth in animal models.
The GammaPod uses tens of thousands of beams of radiation to focus on tumors with pinpoint accuracy, minimizing damage to surrounding healthy tissue. Clinical trials are underway to test the device's effectiveness as an alternative to invasive surgery and traditional radiation therapies.
A study of 601 women with breast cancer found that African-American women were more likely to experience delay in treatment due to type of treatment received or younger age. White women experienced delay if they underwent immediate breast reconstruction following mastectomy.
A large Dutch nationwide cohort study found that women giving birth to multiples after IVF treatment have a higher risk of breast cancer. The study suggests a link between high embryo implantation potential and breast cancer risk, with increased levels of VEGF possibly playing a role.
Researchers at the Walter and Eliza Hall Institute have discovered that BH3-mimetics, currently in clinical trials for leukaemia, could offer hope for treating aggressive oestrogen receptor-positive (ER-positive) breast cancers. The compounds were effective when combined with tamoxifen in preclinical models, improving treatment outcomes.
Research by a University of North Carolina-led team shows that inhibiting MerTK signaling in macrophages can activate the immune system to kill cancer cells, slowing tumor growth and metastasis. The study's findings suggest combining this approach with existing therapies may offer a new avenue for activating anti-tumor immunity.
Removing MerTK from immune cells decreases tumor growth and metastasis in breast, melanoma, and colon cancers. Inhibition of MerTK may stimulate anti-tumor responses and have clinical benefits.